ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,303.27
0.12%
US Tech 100
18,062.00
-0.10%
다우존스 지수
40,003.59
0.34%
Bitcoin
66,674.88
0.60%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Intellia Therapeutics Inc (NTLA)

  7. Intellia Therapeutics Inc (NTLA) 뉴스

NTLA

Intellia Therapeutics (NTLA)

Intellia Therapeutics Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:NTLA
일자시간출처헤드라인심볼기업
2024/05/1005:25Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NTLAIntellia Therapeutics Inc
2024/05/0920:40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTLAIntellia Therapeutics Inc
2024/05/0920:30GlobeNewswire Inc.Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
2024/05/0220:30GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company UpdatesNASDAQ:NTLAIntellia Therapeutics Inc
2024/04/2920:30GlobeNewswire Inc.Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024NASDAQ:NTLAIntellia Therapeutics Inc
2024/03/1820:30GlobeNewswire Inc.Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with CardiomyopathyNASDAQ:NTLAIntellia Therapeutics Inc
2024/03/0606:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
2024/03/0606:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
2024/03/0606:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
2024/03/0606:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
2024/03/0606:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
2024/02/2621:04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NTLAIntellia Therapeutics Inc
2024/02/2407:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTLAIntellia Therapeutics Inc
2024/02/2306:11Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NTLAIntellia Therapeutics Inc
2024/02/2306:02Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NTLAIntellia Therapeutics Inc
2024/02/2221:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTLAIntellia Therapeutics Inc
2024/02/2221:30GlobeNewswire Inc.Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
2024/02/1521:30GlobeNewswire Inc.Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic FibrosisNASDAQ:NTLAIntellia Therapeutics Inc
2024/02/1521:30Business WireIntellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic FibrosisNASDAQ:NTLAIntellia Therapeutics Inc
2024/02/1421:30GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company UpdatesNASDAQ:NTLAIntellia Therapeutics Inc
2024/02/0206:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTLAIntellia Therapeutics Inc
2024/02/0107:00GlobeNewswire Inc.Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of MedicineNASDAQ:NTLAIntellia Therapeutics Inc
2024/01/3006:00Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NTLAIntellia Therapeutics Inc
2024/01/1106:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
2024/01/0906:05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
2024/01/0606:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
2024/01/0606:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
2024/01/0606:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
2024/01/0606:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
2024/01/0606:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
 검색 관련기사 보기:NASDAQ:NTLA

최근 히스토리

COIN
BENDETH
Bend Token
BIT
P22GO5
NLBNPIT22GO5 20240621 40
COIN
PEPEXLETH
PepeXL
BIT
1MPC
Marathon Petro
BOV
LLAO11
Units
POLO
CAPYUSDT
Capybara
BIT
P22KS8
NLBNPIT22KS8 20991231 65...
ASX
BFL
BSP Financial
COIN
BANKETHETH
BankEth
NASDAQ
CKN
TSXV
NID
UNSW
PERPETH
Perpetual
BIT
S29813
Societe Generale Effekten
BOV
BRKM5M
BRASKEM PNA
NASDAQ
TGALD
BIT
1ES
Eversource Energy
Delayed Upgrade Clock
ADVFN Logo

대한민국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유